Pretreatment prediction of individual rheumatoid arthritis patients' response to anti-cytokine therapy using serum cytokine/chemokine/soluble receptor biomarkers

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Uno, Kazuko ^a,b   Yoshizaki, Kazuyuki ^a,d   Iwahashi, Mitsuhiro ^c   Yamana, Jiro ^c   Yamana, Seizo ^c   Tanigawa, Miki ^a   Yagi, Katsumi ^b  

^a OSAKA UNIVERSITY   (Japan)

^b Louis Pasteur Center for Medical Research   (Japan)

^c Hiroshima Memorial Hospital   (Japan)

^d Nagoya Tokushukai General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICYTOKINE; ANTIRHEUMATIC AGENT; CHEMOKINE; CYTOKINE; EOTAXIN; ETANERCEPT; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN GP 130; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; BLOOD; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; SOLUBILITY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; CHEMOKINES; CYTOKINE RECEPTOR GP130; ETANERCEPT; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; REGRESSION ANALYSIS; REMISSION INDUCTION; ROC CURVE; SOLUBILITY; TREATMENT OUTCOME;

EID: 84941347859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132055     Document Type: Article

References (36)

1. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354: 1932-1939. PMID: 10622295
2. van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al. (2005) Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 64: 1582-1587. PMID: 15860509
3. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35-45. PMID: 12528101
4. Arend WP (2002) The mode of action of cytokine inhibitors. J Rheumatol Suppl 65: 16-21. PMID: 12236617
5. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, et al. (2003) Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol 30: 1426-1435. PMID: 12858437
6. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761-1769. PMID: 15188351
7. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372: 375-382. doi: 10.1016/S0140-6736(08)61000-4 PMID: 18635256
8. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997. doi: 10.1016/S0140-6736 (08)60453-5 PMID: 18358926
9. Nishimoto N, Takagi N (2010) Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. Mod Rheumatol 20: 539-547. doi: 10.1007/s10165-010-0328-0 PMID: 20617358
10. Tanaka T, Ogata A, Narazaki M (2010) Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 6: 843-854. doi: 10.1586/eci.10.70 PMID: 20979549
11. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A (2011) Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 70: 755-759. doi: 10.1136/ard.2010.139725 PMID: 21187298
12. Soken-Nakazawa J S, Yoshizaki K (2015) Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opin Drug Metab Toxicol 11: 307-316. doi: 10.1517/17425255.2015.992779 PMID: 25491492
13. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, et al. (2009) Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68: 914-921. doi: 10.1136/ard.2008.092254 PMID: 18662933
14. van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. (2010) Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. J Rheumatol 37: 2237-2246. doi: 10.3899/jrheum. 100208 PMID: 20889601
15. Aga AB, Lie E, Uhlig T, Olsen IC, Wierod A, Kalstad S, et al. (2013) Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NORDMARD study 2000-2010. Ann Rheum Dis.
16. Navarro-Millan I, Curtis JR (2013) Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 25: 384-390. doi: 10. 1097/BOR.0b013e32835fc62e PMID: 23511719
17. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, et al. (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis.
18. Solomon DH, Bitton A, Katz JN, Radner H, Brown EM, Dougados M, et al. (2014) Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? Arthritis Rheumatol 66: 775-782. doi: 10.1002/art. 38323 PMID: 24757129
19. Lindstrom TM, Robinson WH (2010) Biomarkers for rheumatoid arthritis: making it personal. Scand J Clin Lab Invest Suppl 242: 79-84. doi: 10.3109/00365513.2010.493406 PMID: 20515283
20. Marotte H, Miossec P (2010) Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. Joint Bone Spine 77: 297-305. doi: 10.1016/j.jbspin.2010.02.026 PMID: 20478724
21. Conaghan PG (2011) Predicting outcomes in rheumatoid arthritis. Clin Rheumatol 30 Suppl 1: S41-47. doi: 10.1007/s10067-010-1639-4 PMID: 21203790
22. van den Broek M, Visser K, Allaart CF, Huizinga TW (2013) Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 13: 463-469. doi: 10.1016/j.coph. 2013.03.006 PMID: 23578763
23. Ortea I, Roschitzki B, Ovalles JG, Longo JL, de la Torre I, Gonzalez I, et al. (2012) Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: an exploratory analysis. J Proteomics 77: 372-382. doi: 10.1016/j.jprot. 2012.09.011 PMID: 23000593
24. Serada S, Naka T (2014) Screening for novel serum biomarker for monitoring disease activity in rheumatoid arthritis using iTRQ technology-based quantitative proteomic approach. Methods in Molecular biology 1142: 99-110. doi: 10.1007/978-1-4939-0404-4-12 PMID: 24706280
25. Bienkowska JR, Dalgin GS, Batliwalla F, Allaire N, Roubenoff R, Gregersen PK, et al. (2009) Convergent Random Forest predictor: methodology for predicting drug response from genome-scale data applied to anti-TNF response. Genomics 94: 423-432. doi: 10.1016/j.ygeno.2009.08.008 PMID: 19699293
26. Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, et al. (2014) Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis.
27. Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, Takeuchi T (2014) Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis 73: 945-947. doi: 10.1136/annrheumdis-2013-204137 PMID: 24336338
28. Sanayama Y, Ikeda K, Saito Y, Kagami S, Yamagata M, Furuta S, et al. (2014) Prediction of therapeutic responses to tocilizumab in patients with rheumatoid arthritis: biomarkers identified by analysis of gene expression in peripheral blood mononuclear cells using genome-wide DNA microarray. Arthritis Rheumatol 66: 1421-1431. doi: 10.1002/art.38400 PMID: 24591094
29. Nowell MA, Richards PJ, Horiuchi S, Yamamoto N, Rose-John S, Topley N, et al. (2003) Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol 171: 3202-3209. PMID: 12960349
30. Boettger MK, Leuchtweis J, Kummel D, Gajda M, Brauer R, Schaible HG (2010) Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther 12: R140. doi: 10.1186/ar3079 PMID: 20626857
31. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Ann Rheum Dis 66: 407-409. PMID: 16926186
32. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K (2004) IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 314: 363-369. PMID: 14733913
33. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. (2008) Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J Immunol 180: 3492-3501. PMID: 18292576
34. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K (2010) Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116: 3627-3634. doi: 10.1182/blood- 2010-03-271791 PMID: 20644113
35. Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, et al. (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521-1529. PMID: 12794819
36. Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8: 1237-1247. doi: 10.7150/ijbs.4989 PMID: 23136552